Want to see IN:SUPRIYA full AI Analyst Report?

Supriya Lifescience Limited (SUPRIYA) Price & Analysis

0 Followers

SUPRIYA Stock Chart & Stats

₹751.00

-₹18.10(-2.41%)

At close: Jan 08 4:00 PM EST

₹751.00

-₹18.10(-2.41%)

Day’s Range― - ―

52-Week Range₹545.65 - ₹1,085.50

Previous CloseN/A

Volume168.68K

Average Volume (3M)21.15K

Market Cap

₹72.88B

Enterprise Value₹44.75K

Total Cash (Recent Filing)₹788.67M

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)36.9

Beta1.22

Next Earnings

Nov 11, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.11%

Share Statistics

EPS (TTM)24.65

Shares Outstanding80,482,800

10 Day Avg. Volume20,163

30 Day Avg. Volume21,147

Financial Highlights & Ratios

PEG Ratio1.92

Price to Book (P/B)3.78

Price to Sales (P/S)5.46

P/FCF Ratio105.21

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)29.9

Revenue Forecast (FY)₹9.94B

Bulls Say, Bears Say

Bulls Say

Strong Revenue GrowthSustained revenue expansion indicates improving demand and market reach across the company’s API portfolio. The recovery from the 2023 decline and double-digit 2026 growth provide a stronger base for capacity utilization, operating leverage, and continued investment over the next several quarters.

Conservative Balance SheetVery low leverage reduces interest burden and financial risk, giving Supriya greater flexibility to fund manufacturing capacity, regulatory requirements, or other growth initiatives internally. Meaningful equity growth also strengthens the asset base and improves resilience if industry conditions become less favorable.

Improved Operating Cash FlowStrong recent operating cash flow improves earnings quality and supports internal funding capacity. This gives the company more ability to finance ongoing operations and strategic investment without relying heavily on borrowing, complementing its conservative balance sheet and supporting durable business growth.

Bears Say

Free-cash-flow VolatilityThe recent free-cash-flow rebound is encouraging, but the preceding three years of negative generation show that cash conversion can be uneven. Periods of heavy investment or working-capital swings may reduce funding flexibility and make internally generated cash less predictable over time.

Margin VolatilityFluctuating margins can make earnings less predictable even when revenue continues to grow. The stated sensitivity to product mix, pricing, and costs suggests that changes in the API portfolio or competitive conditions could pressure profitability and limit the consistency of future operating returns.

Moderating Returns On EquityModerating return on equity indicates that the company may be generating less profit relative to its expanding equity base than it did at earlier peaks. If this normalization continues, it could reduce capital efficiency and place greater importance on sustaining growth and improving margins.

Supriya Lifescience Limited News

Supriya Lifescience Schedules Virtual Investor Meet, Posts Presentation Online

The latest announcement is out from Supriya Lifescience Limited ( ($IN:SUPRIYA) ). Supriya Lifescience Limited has announced that...

21h ago

Supriya Lifescience Seeks Shareholder Nod to Reappoint Whole Time Director via E-Voting

Supriya Lifescience Limited ( ($IN:SUPRIYA) ) has issued an announcement. Supriya Lifescience Limited has initiated a postal ballot...

2M ago

Supriya Lifescience Confirms SEBI Compliance on Dematerialised Securities

Supriya Lifescience Limited ( ($IN:SUPRIYA) ) has shared an announcement. Supriya Lifescience Limited has reported that its registrar...

2M ago

Supriya Lifescience Reports Customs Probe Into Senior Sales Executive

Supriya Lifescience Limited ( ($IN:SUPRIYA) ) has shared an update. Supriya Lifescience has disclosed that its General Manager...

3M ago

Supriya Lifescience Publishes Postal Ballot Notice in Newspapers

Supriya Lifescience Limited ( ($IN:SUPRIYA) ) has provided an update. Supriya Lifescience Limited notified the stock exchanges that...

6M ago

Supriya Lifescience Closes Trading Window Ahead of Q3 FY26 Results

An announcement from Supriya Lifescience Limited ( ($IN:SUPRIYA) ) is now available. Supriya Lifescience Limited has announced the...

9M ago

Supriya Lifescience Schedules Earnings Call to Discuss Financial Performance

Supriya Lifescience Limited ( ($IN:SUPRIYA) ) has issued an announcement. Supriya Lifescience Limited has announced an upcoming earnings...

11M ago

Supriya Lifescience Discloses Key Managerial Personnel Details

The latest announcement is out from Supriya Lifescience Limited ( ($IN:SUPRIYA) ). Supriya Lifescience Limited has announced the...

2y ago

SUPRIYA FAQ

What was Supriya Lifescience Limited’s price range in the past 12 months?

Supriya Lifescience Limited lowest stock price was ₹545.65 and its highest was ₹1085.50 in the past 12 months.

What is Supriya Lifescience Limited’s market cap?

Supriya Lifescience Limited’s market cap is ₹72.88B.

When is Supriya Lifescience Limited’s upcoming earnings report date?

Supriya Lifescience Limited’s upcoming earnings report date is Nov 11, 2026 which is in 51 days.

How were Supriya Lifescience Limited’s earnings last quarter?

Supriya Lifescience Limited released its earnings results on Aug 13, 2026. The company reported ₹3 earnings per share for the quarter, missing the consensus estimate of ₹9.3 by -₹6.3.

Is Supriya Lifescience Limited overvalued?

According to Wall Street analysts Supriya Lifescience Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Supriya Lifescience Limited pay dividends?

Supriya Lifescience Limited pays a Annually dividend of ₹1 which represents an annual dividend yield of 0.11%. See more information on Supriya Lifescience Limited dividends here

What is Supriya Lifescience Limited’s EPS estimate?

Supriya Lifescience Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Supriya Lifescience Limited have?

Supriya Lifescience Limited has 80,482,800 shares outstanding.

What happened to Supriya Lifescience Limited’s price movement after its last earnings report?

Supriya Lifescience Limited reported an EPS of ₹3 in its last earnings report, missing expectations of ₹9.3. Following the earnings report the stock price went down -2.183%.

Which hedge fund is a major shareholder of Supriya Lifescience Limited?

Currently, no hedge funds are holding shares in IN:SUPRIYA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Supriya Lifescience Limited

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.